Aurobindo Pharma Ltd. on Tuesday announced a share buyback of Rs 800 crore, with the company planning to repurchase a total of 54.23 lakh shares.
The equity will be repurchased at an amount of Rs 1,475, it informed the exchanges. The record date, to determine the shareholders eligible for the buyback, has been fixed as April 17.
The buyback offer will open on Thursday, April 23, and close on Wednesday, April 29, Aurobindo Pharma said in the filing. The last date of receipt of completed tender forms and other specified documents by the registrar has been fixed as April 29, whereas May 7 is the last date for completion of settlement of bids, it added.
"The buyback size constitutes 3.93% and 2.62% of the aggregate of the total paid-up equity share capital and free reserves (including securities premium) of the company as per the latest audited standalone and consolidated financial statements," the filing stated.
The buyback, said Aurobindo Pharma, will help the firm to reward its shareholders and enhance the overall return to shareholders. It is also expected to improve "earnings per share" and other key ratios such as return on net worth and return on assets over a period of time, the company added.
"The buyback will not result in any benefit to promoter and promoter group or any directors of the company except to the extent of the cash consideration received by them from the company pursuant to their respective participation in the buyback," it further noted.
Before the buyback announcement, shares of Aurobindo Pharma closed 1.41% higher at Rs 1387.05 apiece on the BSE, as compared to a 0.96% climb in the benchmark Sensex. The drugmaker's stock has risen by 15.5% over the past 12 months, and by 16.3% in 2026 so far.
ALSO READ: Aurobindo Pharma Q3 Results: Profit Misses Estimates, Revenue 'Highest Ever'
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
